A Multicenter Retrospective Study of Avelumab First-Line Maintenance and Subsequent Therapies for Locally Advanced and Metastatic Urothelial Carcinoma: Subgroup Analysis of First-Line Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, and Gemcitabine Plus Cisplatin in the Japan AVElumab MAintenance and Continuous Treatment Study (JAVEMACS).

A notable trend was identified in laboratory results between the start of 1L PBC and start of avelumab maintenance therapy in both groups; the percentage of patients with hemoglobin levels <10 g/dL tended to rise at the start of avelumab maintenance therapy, whereas the percentage of patients with inflammatory markers such as C-reactive protein (CRP) levels <0.3 mg/dL tended to decline from the start of 1L PBC to start of avelumab maintenance therapy.

also in 2,105 other papers

The EORTC Phase 3 study comparing dose-dense (dd)MVAC and conventional MVAC in aUC revealed that ddMVAC was better tolerated than conventional MVAC and showed a trend towards longer progression-free survival (PFS) and OS rates, with a median OS of 15.1 months [ 15 ].

also in 33,226 other papers